WallStSmart
AKBA

Akebia Ther

NASDAQ: AKBA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$1.36
-4.23% today

Updated 2026-04-29

Market cap
$364.82M
P/E ratio
P/S ratio
1.55x
EPS (TTM)
$-0.02
Dividend yield
52W range
$1 – $4
Volume
2.7M

Akebia Ther (AKBA) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
+130.9%
Last 4 quarters
Revenue YoY growth
+23.9%
Most recent quarter
EPS YoY growth
+50.0%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-3.5%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
-11.3%
2025-11-10
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-12$-0.05-2600.0%$1.40$1.46+4.3%
2025-11-10$0.00+105.0%$2.04$1.81-11.3%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$0.00$-0.05-2600.0%$57.62M+23.9%
2025-09-30$-0.04$0.00+105.0%$58.77M+57.0%
2025-06-30$-0.02$0.03+233.5%$62.47M+43.1%
2025-03-31$-0.08$0.02+130.9%$57.34M+75.8%
2024-12-31$-0.08$-0.10-33.3%$46.50M-17.3%
2024-09-30$-0.06$-0.10-66.7%$37.43M-11.0%
2024-06-30$-0.05$-0.04+20.0%$43.65M-22.6%
2024-03-31$-0.08$-0.09-12.5%$32.61M-18.5%
2023-12-31$-0.04$0.00+108.0%$56.20M
2023-09-30$-0.08$-0.08+0.0%$42.05M
2023-06-30$-0.02$-0.06-200.0%$56.38M
2023-03-31$-0.15$-0.14+6.7%$40.01M

Frequently asked questions

Has Akebia Ther beaten earnings estimates?
Akebia Ther has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of +130.9% over the last 1 quarters.
How does AKBA stock react to earnings?
AKBA stock has moved an average of -3.5% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Akebia Ther's revenue growth rate?
Akebia Ther reported year-over-year revenue growth of +23.9% in its most recent quarter, with EPS growing +50.0% year-over-year.